News | August 06, 2024
Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr
Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024
Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024
Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Revolutionary technology will further boost OneSource’s scientific services offerings
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
